Análisis opcionales del producto
Con tu permiso, usamos análisis limitados y respetuosos con la privacidad para entender qué recorridos de investigación funcionan. No usamos rastreadores publicitarios ni grabación de sesiones. Puedes cambiar esta opción en Preferencias. Lee la Política de privacidad.
Eli Lilly and Company's published Sell conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $1.02T | |
|---|---|---|
| Revenue (ttm) | 79.7B | |
| Net income (ttm) | 26.7B | |
| EPS (ttm) | $29.8 | |
| Shares out | 891.4M | |
| P/E (trailing) | 43.3x | |
| P/E (forward) | 24.6x | |
| Dividend | $6.92 (0.53%) | |
| Volume | 1,523,010 | |
| Beta | 0.45 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $28.32B | $28.54B | $34.12B | $45.04B | $65.18B | +23.2% |
| Gross profit | $21.01B | $21.91B | $27.04B | $36.62B | $54.62B | +27.0% |
| Operating income | $6.50B | $7.14B | $7.04B | $13.46B | $26.37B | +42.0% |
| Net income | $5.58B | $6.24B | $5.24B | $10.59B | $20.64B | +38.7% |
| EPS (diluted) | $8.17 | $7.94 | $6.32 | $13.00 | $24.21 | +31.2% |
| EBITDA | $8.04B | $8.66B | $8.57B | $15.23B | $27.94B | +36.5% |
| R&D | $6.93B | $7.19B | $9.31B | $10.99B | $13.34B | +17.8% |
| SG&A | $6.14B | $6.07B | $6.94B | $8.13B | $11.09B | +15.9% |
Recent company headlines from major financial publishers.
The base path supports Fair value, but the report-date price remains above that estimate.
Upside persists only if stronger growth also improves margins and cash without creating a permanent maintenance burden.
| Ke ↓ / g → | 2.5% | 3.0% | 3.5% | 4.0% | 4.5% |
|---|---|---|---|---|---|
| 5.8% | $1,020 | $1,105 | $1,238 | $1,479 | $2,124 |
| 6.8% | $875 | $916 | $972 | $1,051 | $1,175 |
| 7.8% | $782 | $806 | $836 | $875 | $927 |
| 8.8% | $716 | $731 | $749 | $771 | $799 |
| 9.8% | $664 | $674 | $686 | $701 | $718 |
Upcoming earnings date and setup when available.
La calificación que llevaba la edición de análisis publicada cada mes. Una calificación compara el precio en la fecha del análisis con el valor razonable; no es un registro de si la valoración acertó.
| Año | ene | feb | mar | abr | may | jun | jul | ago | sept | oct | nov | dic |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
